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The gene encompasses 33 kb of DNA; 12 exons. 
Transcription 
2.3 kb nucleotides mRNA. 1476 b open reading frame. 
Protein 
Description 
491 amino acids; 90 kDa protein. 
Expression 
Expression of MDM2 during embryogenesis was 
studied in mice. During 14.5 to 18.5 days of prenatal 
development, the nasal respiratory epithelium expresses 
high levels of MDM2 RNA and protein in both wild 
type and p53 null embryos. MDM2 expression during 
development is tissue-specific and is independent of 
p53. The mdm2 basal mRNA expression appears 
relatively moderate in most organs in adult mice. 
MDM2 gene was overexpressed in some types of 
leukemias and lymphomas. Overexpression was 
significantly more frequent in the low-grade type of B-
cell non-Hodgkin's lymphoma (B-NHL) than in the 
intermediate/high grade types of lymphoma and the 
overexpression was also significantly more frequent in 
the advanced rather than the earlier stages of B-cell 
chronic lymphocytic leukemia (B-CLL). 
Localisation 
MDM2 protein was found in nucleus and cytoplasm. 
Function 
MDM2 was originally cloned from transformed 
Balb/c3T3 cell line called 3T3DM and was identified 
as an amplified oncogene in murine cell lines. MDM2 
was shown to be amplified in approximately 30% of 
osteosarcomas and soft tissue tumors and was 
subsequently found to act as an ubiquitin ligase 
promoting proteasome dependent degradation of p53. 
MDM2 is also a transcriptional target of p53 such that 
p53 activity controls the expression and protein level of 
its own negative regulator, providing for an elegant 
feedback loop. MDM2 inhibits the G1 arrest and 
apoptosis functions of the p53 tumor suppressor 
protein. The MDM2-p53 complex also inhibits p53 
mediated transactivation. 
MDM2 knockout mouse embryos died during 
development and deletion of the p53 gene rescues 
MDM2 null embryos. These studies suggested that p53 
is lethal in the absence of MDM2 during mouse 
development and MDM2 is a critical regulator to 
control p53 activity. 
In addition, MDM2 involves nuclear export of p53 
protein. Interaction between the p53 and MDM2 is not 
sufficient to mediate p53 degradation. The p53-MDM2 
complex must be shuttled from the nucleus to the 
cytoplasm in order for p53 degradation. 
Besides, the MDM2 protein also promotes RB 
(retinoblastoma) protein degradation in a proteasome-
dependent manner in human tumor cell lines. MDM2 
overexpression contributes to cancer development in 
part by destabilizing RB. 
Interaction between MDM2 and the tumor suppressor 
genes p53 and Rb lead to deregulate cell proliferaton 
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and apoptosis. MDM2 is a key factor in human 
tumorigenesis. 
Both MDM2 and Pirh2 (RCHY1) proteins are p53 
ubiquitin-protein E3 ligases promoting for degradation 
of p53 protein. However, MDM2 operates in a distinct 
manner from Pirh2 in response to DNA damage in 
cancer cells. MDM2 protein is reduced or absent in the 
p53 null cells compared to the p53 positive cells, 
Whereas, Pirh2 expression is not affected by the statu  
of p53. 
A single nucleotide polymorphism (SNP309) found in 
the MDM2 promoter is shown to increase the affinity 
of the transcriptional activator Sp1, resulting in higher 
levels of MDM2 RNA and protein and the subsequent 
attenuation of the p53 pathway. In humans, SNP309 is 
shown to associate with accelerated tumor formation in 
both hereditary and sporadic cancers. 
Homology 
The MDM2 gene has been identified in various 
organisms including mammals, amphibians and fishes. 
It belongs to the ring finger ubiquitin protein E3 ligase 
family, containing Conserved RING-finger Domain. 
Mutations 
Note: MDM2 mutations are uncommon. Point 
mutations were reported in human cancers. 
Implicated in 
Soft tissue tumors and osteosarcomas 
Disease 
A set of data of MDM2 amplification based on 3889 
samples from tumors or xenografts from 28 tumor 
types from previously published sources was collected. 
The overall frequency of MDM2 amplification in these 
human tumors was 7%. Gene amplification was 
observed in 19 tumor types, with the highest frequency 
observed in soft tissue tumors (20%), osteosarcomas 
(16%) and esophageal carcinomas (13%). 
Oncogenesis 
MDM2 is amplified in many cancers. Because the 
MDM2 is an ubiquitin-protein ligase that promotes p53 
protein degradation, the increased MDM2 protein could 
play an important role in tumorigenesis, especially in 
the development of soft tissue tumors, osteosarcomas 
and esophageal carcinomas. 
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